ZURA Stock Analysis: Buy, Sell, or Hold?
ZURA - Zura Bio Limited Class A Ordinary Shares
$5.64
-0.29 (-4.97%)
▼
5d:
+1.17%
30d:
-14.88%
90d:
+21.18%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
ZURA is down 15.5% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 31 OI. Call ratio: 73% View Scanner →
Strength: 10.0/10
Get Alerted When ZURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ZURA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ZURA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: ZURA is currently trading at $5.63, which is considered oversold relative to its 30-day fair value range of $5.87 to $6.88.
Technical Outlook: Technically, ZURA is in a strong uptrend. Immediate support is located at $5.23, while resistance sits at $6.61. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.50 (+161.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZURA is in a strong uptrend. Immediate support is located at $5.23, while resistance sits at $6.61. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.50 (+161.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.87 -
$6.88
Company Quality Score
54/100
(HOLD)
Options IV Signal
49th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 49th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 161.4% below Wall St target ($15.50)
Fair Price Analysis
30-Day Fair Range
$5.87 -
$6.88
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$1.17
(20.8%)
Support & Resistance Levels
Support Level
$5.23
Resistance Level
$6.61
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-59.30
Wall Street Target
$15.50
(+161.4%)
Share & Embed Analysis
Last updated: March 30, 2026 1:41 PM ET
Data refreshes hourly during market hours. Next update: 2:41 PM
Data refreshes hourly during market hours. Next update: 2:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZURA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ai Biotechnology Llc
BUY
2000000 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 47 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 51 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
